Loading stock data…
Entrada Therapeutics, Inc. (TRDA)
$7.52+0.39 (+5.47%)
After Hours$7.52+0.00 (+0.00%)· Last close Sep 8
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Entrada Therapeutics, Inc. in the Healthcare sector is trading at $7.52 with a market capitalization of $274M. Wall Street consensus targets $19.00 (4 analysts), implying a +152.7% move over the next 12 months. The stock is currently 54% below its 52-week high of $16.45, remaining 22.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +152.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $875,000↓ | $1.30M↓ | $1.61M↓ | $1.95M↓ | $20.56M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$42.30M↓ | -$42.21M↑ | -$47.05M↓ | -$46.85M↓ | -$21.79M |
| Net Income | -$39.72M↓ | -$39.16M↑ | -$44.13M↓ | -$43.10M↓ | -$17.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$274.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.39%
Volume
Today's trading volume
487,465
Recent News
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of 0.00% and -3.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duchenne muscular dystrophy, or DMD, who have mutations amenable to exon 44 skipping
Entrada’s stock drops as DMD drug’s efficacy falls short
At a 6 mg/kg dose, ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded by Novartis’ del-zota.